The Oncologist, Vol. 12, No. 1, 107-113, January 2007; doi:10.1634/theoncologist.12-1-107
© 2007 AlphaMed Press
Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma
Edwin P. Rocka,
Vicki Goodmana,
Janet X. Jiangb,
Kooros Mahjoobb,
S. Leigh Verboisa,
David Morsea,
Ramzi Daghera,
Robert Justicea,
Richard Pazdurc
a Division of Drug Oncology Products,
b Office of Biostatistics, and
c Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
Key Words. Sunitinib • Sutent • Gastrointestinal stromal tumor • Renal cell carcinoma
Correspondence:
Edwin P. Rock, M.D., Ph.D., Food and Drug Administration, Division of Drug Oncology Products, 10903 New Hampshire Avenue, Bldg. 22, Rm. 2133, Silver Spring, Maryland 20903, USA. Telephone: 301-796-2330; Fax: 301-796-9845; e-mail: edwin.rock{at}fda.hhs.gov
On January 26, 2006, sunitinib (Sutent) received regular approval as monotherapy for the treatment of patients with gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate (Gleevec). Time-to-tumor progression (TTP) of sunitinib-treated patients was superior to that of placebo-treated patients. Median TTP of sunitinib-treated patients was 27.3 weeks, compared with 6.4 weeks for placebo-treated patients (p < .0001). Partial responses were observed in 6.8% of sunitinib-treated patients and no placebo-treated patients. Sunitinib also received accelerated approval on January 26, 2006, as monotherapy for treatment of advanced renal cell carcinoma (RCC). In two single-arm trials of sunitinib in patients with metastatic RCC, partial responses were observed in 25.5% (95% confidence interval [CI], 17.5, 34.9) and 36.5% (95% CI, 24.7, 49.6) of patients. Median response durations in the two trials were 27.1 weeks (95% CI, 24.4, incalculable) and 54 weeks (95% CI, 34.3, 70.1). Treatment-emergent adverse events in sunitinib-treated patients included diarrhea, mucositis, skin abnormalities, altered taste, electrolyte abnormalities, hypertension, and diminution in left ventricular ejection fraction. Cardiac safety of sunitinib in patients with preexisting cardiac abnormalities remains unknown. Based on nonclinical findings, physicians prescribing sunitinib should monitor for adrenal insufficiency in patients who undergo stressors such as surgery, trauma, or severe infection. Caution should be exercised when administering sunitinib in combination with known CYP3A4 inducers or inhibitors.
This article has been cited by other articles:

|
 |

|
 |
 
A. du Bois, J. Huober, P. Stopfer, J. Pfisterer, P. Wimberger, S. Loibl, V. L. Reichardt, and P. Harter
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
Ann. Onc.,
February 1, 2010;
21(2):
370 - 375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Basille, M. Andrejak, H. Bentayeb, M. Kanaan, C. Fournier, E. Lecuyer, M. Boutemy, R. Garidi, Y. Douadi, and C. Dayen
Bronchial Fistula Associated with Sunitinib in a Patient Previously Treated with Radiation Therapy
Ann. Pharmacother.,
February 1, 2010;
44(2):
383 - 386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sridhara, J. R. Johnson, R. Justice, P. Keegan, A. Chakravarty, and R. Pazdur
Review of Oncology and Hematology Drug Product Approvals at the US Food and Drug Administration Between July 2005 and December 2007
J Natl Cancer Inst,
January 29, 2010;
(2010):
djp515v1 - djp515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Mross, M. Stefanic, D. Gmehling, A. Frost, F. Baas, C. Unger, R. Strecker, J. Henning, B. Gaschler-Markefski, P. Stopfer, et al.
Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors
Clin. Cancer Res.,
January 1, 2010;
16(1):
311 - 319.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Muller-Deile, V. Brocker, V. Grunwald, M. Hiss, A. Bertram, S. Kubicka, A. Ganser, H. Haller, and M. Schiffer
Renal side effects of VEGF-blocking therapy
NDT Plus,
December 17, 2009;
(2009)
sfp175v1.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Cersosimo
Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2
Am. J. Health Syst. Pharm.,
September 15, 2009;
66(18):
1625 - 1633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Bornstein
Predisposing Factors for Adrenal Insufficiency
N. Engl. J. Med.,
May 28, 2009;
360(22):
2328 - 2339.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Illouz, S. Laboureau-Soares, S. Dubois, V. Rohmer, and P. Rodien
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
Eur. J. Endocrinol.,
March 1, 2009;
160(3):
331 - 336.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Shukla, R. W. Robey, S. E. Bates, and S. V. Ambudkar
Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2
Drug Metab. Dispos.,
February 1, 2009;
37(2):
359 - 365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Winn, S. Ellis, P. Savage, S. Sampson, and J. E. Marsh
Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?
Nephrol. Dial. Transplant.,
February 1, 2009;
24(2):
673 - 675.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Patyna, C. Arrigoni, A. Terron, T.-W. Kim, J. K. Heward, S. L. Vonderfecht, R. Denlinger, S. E. Turnquist, and W. Evering
Nonclinical Safety Evaluation of Sunitinib: A Potent Inhibitor of VEGF, PDGF, KIT, FLT3, and RET Receptors
Toxicol Pathol,
December 1, 2008;
36(7):
905 - 916.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Guenova, H. O. Weber, B. Voykov, G. Metzler, V. Mitev, M. Berneburg, W. Hoetzenecker, and M. Rocken
Palmar-Plantar Erythrodysesthesia Secondary to Sunitinib Treatment Resulting in Necrotic Foot Syndrome Aggravated by Background Diabetic Vascular Disease
Arch Dermatol,
August 1, 2008;
144(8):
1081 - 1082.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Huang, Y. Ding, W.-M. Luo, S. Bender, C.-N. Qian, E. Kort, Z.-F. Zhang, K. VandenBeldt, N. S. Duesbery, J. H. Resau, et al.
Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis In vivo
Cancer Res.,
January 1, 2008;
68(1):
81 - 88.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2007 by AlphaMed Press.
|
|